GSK 561679,
GSK-561679,
GSK561679,
NBI 77860,
NBI-77860,
NBI77860,
VERUCERFONT,
885220-61-1,
GSK561679A,
GSK 561679A,
UNII-X60608B091,
NBI-77860,
GSK561679,
X60608B091,
GSK561679;3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine,
NBI 77860,
Verucerfont [USAN:INN],
GSK 561679,
GSK-561679,
Verucerfont (USAN/INN),
Verucerfont,GSK561679,
SCHEMBL205309,
CHEMBL1287935,
EX-A1718,
BDBM50417503,
ZINC34661169,
CS-8099,
DB12512,
SB17107,
AC-30339,
HY-14875,
A16950,
D09695,
3-(4-Methoxy-2-methylphenyl)-2,5-dimethyl-N-((1S)-1-(3-methyl-1,2,4-oxadiazol-5- yl)propyl)pyrazolo(1,5-a)pyrimidin-7-amine,
3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-((S)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl)pyrazolo[1,5-a]pyrimidin-7-amine,
Pyrazolo(1,5-a)pyrimidin-7-amine, 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-((1S)- 1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl)-,
Verucerfont [USAN],
D0ZC0M,
NBI77860,
ACN-053196,
CID11596613,
CID 11545949,
C556497,
3-(4-METHOXY-2-METHYLPHENYL)-2,5-DIMETHYL-N-[(1S)-1-(3-METHYL-1,2,4-OXADIAZOL-5-YL)PROPYL]PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE,